Acino International AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.
This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.
This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.
Scope
- Business description - A detailed description of the company’s operations and business divisions.
- Corporate strategy - The publisher's summarization of the company’s business strategy.
- SWOT analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives’ employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details.
Highlights
Acino International AG (Acino), formerly Acino Holding AG, manufactures and commercializes generic and prescription pharmaceuticals in novel drug delivery forms. The company focuses on the therapeutic areas of oncology, cardiology and metabolism, central nervous system, gastroenterology, infectiology, pain and rheumatology, respiratory, urology and women’s health, among others. It also offers business-to-business services such as product development and contract manufacturing, among others. The company's drug delivery technologies focus on modified release oral forms and oral dispersible forms. Acino has manufacturing facilities in Estonia, Switzerland, and Ukraine. The company markets products mainly in the Middle East, Africa, Latin America, Europe, and Asia. Acino is headquartered in Zurich, Switzerland.Acino International AG Key Recent Developments
- Aug 14023: Acino announces collaboration with Janssen to strengthen patient access in South Africa
- Jun 26023: Acino appoints Max Sorokin as CFO
Reasons to Buy
- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
- Understand and respond to your competitors’ business structure and strategies with the publisher's detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
- Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Table of Contents
Section 1 - About the Company
Section 2 - Company Analysis
Section 3 - Company’s Lifesciences Financial Deals and Alliances
Section 4 - Company’s Recent Developments
Section 5 - Appendix
List of Tables
List of Figures
Samples
LOADING...
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Wacker Biotech GmbH
- Basilea Pharmaceutica Ltd
- Actelion Pharmaceuticals Ltd
- Siegfried Holding AG
- Grunenthal GmbH
- Wacker Biotech GmbH
- Siegfried Holding AG
- Siegfried Hameln Service GmbH
- Grunenthal GmbH
- Basilea Pharmaceutica Ltd
- Actelion Pharmaceuticals Ltd